论文部分内容阅读
目的观察纤溶酶联合低分子肝素钠治疗进展性脑梗死的临床疗效与安全性,探讨进展性脑梗死的有效治疗方法。方法将85例进展性脑梗死患者随机分为治疗组与对照组,两组均给予常规治疗,治疗组予纤溶酶联合低分子肝素钠治疗;对照组单用低分子肝素钠,比较两组治疗前后神经功能改善情况及凝血指标变化。结果治疗组患者的神经功能缺损评分与对照组相比明显改善,差异有统计学意义(P<0.05),血液流变学指标:凝血酶原时间和部分凝血活酶时间明显延长,国际标准化比率升高,纤维蛋白原降低,无明显不良反应发生。结论纤溶酶联合低分子肝素治疗进展性脑梗死在10 d内有效率显著高于对照组(P<0.05),疗效肯定,且副作用少,用药安全,是治疗进展性脑梗死较理想的药物。
Objective To observe the clinical efficacy and safety of plasmin combined with low molecular weight heparin in the treatment of patients with progressive cerebral infarction and explore the effective treatment of progressive cerebral infarction. Methods Eighty-five patients with progressive cerebral infarction were randomly divided into treatment group and control group. Both groups were given routine treatment. The treatment group was given plasmin combined with low molecular weight heparin sodium. The control group was given low molecular weight heparin sodium alone. Changes of neurological function and changes of coagulation index before and after treatment. Results Compared with the control group, the score of neurological deficit in the treatment group was significantly improved (P <0.05), and the indexes of hemorheology: prothrombin time and partial thromboplastin time were significantly longer, and the international standardization ratio Increased, decreased fibrinogen, no significant adverse reactions occurred. Conclusions The effective rate of plasmin combined with low molecular weight heparin in treating progressive cerebral infarction within 10 days is significantly higher than that of the control group (P <0.05), and the curative effect is definite with less side effects and medication safety, which is an ideal drug for the treatment of progressive cerebral infarction .